Hutch News

Hutch News

Stories tagged 'Acute Lymphoblastic Leukemia'

Good News at Fred Hutch

Celebrating faculty and staff achievements

Sept. 14, 2017

An immunotherapy technology developed by Dr. Brian Till with Dr. Oliver Press at Fred Hutchinson Cancer Research Center has been licensed by Mustang Bio Inc., a subsidiary of the biopharmaceutical company Fortress Biotech Inc. The exclusive, worldwide license, announced Sept. 14 by Mustang Bio, will allow a new type of CAR (chimeric antigen receptor) T-cell therapy to be tested in a clinical trial as a treatment for B-cell non-Hodgkin lymphomas. The novel immunotherapy targets CD20, a protein marker on cancer cells in lymphoma.

View story >


93 percent of advanced leukemia patients in remission after immunotherapy

‘Exciting’ but early results from trial of engineered immune cells

April 25, 2016 | By Susan Keown / Fred Hutch News Service

After her immune cells were genetically engineered to target her cancer, Kristin Kleinhofer's leukemia disappeared. The trial was her and her family's 'last hope'.

View story >


Good News at Fred Hutch

Dr. Roland Walter receives two grant awards for acute leukemia research; Dr. Jonathan Bricker to keynote behavioral therapy conference; Dr. Benjamin Anderson chairs NCCN committee that publishes clinical-practice guidelines for cervical cancer

Aug. 27, 2015 | By Fred Hutch staff

Dr. Roland Walter receives two grant awards for acute leukemia research; Dr. Jonathan Bricker to keynote behavioral therapy conference; Dr. Benjamin Anderson chairs NCCN committee that publishes clinical-practice guidelines for cervical cancer

View story >


A lifetime later, a bone marrow donor and recipient return to Fred Hutch

25 years ago, Jennifer Monteleone donated her marrow to her 6-year-old brother, Michael

July 16, 2015 | By Megan Herndon / Fred Hutch News Service

When Jennifer Monteleone was only a year old and Michael was 6, her bone marrow was used in a transplant to eradicate his leukemia. Twenty-five years later, the siblings recently visited Fred Hutchinson Cancer Research Center.

View story >


Pediatric transplant symposium June 29

Register for symposium and retirement reception celebrating Dr. Jean Sanders' four-decade career

June 18, 2012

Dr. Jean Sanders' profound impact on the science of pediatric transplantation will be celebrated June 29 at a Fred Hutchinson Cancer Research Center symposium and retirement reception: "Advances in Pediatric Hematopoietic Cell Transplantation and Cellular Therapy: The Influence of a Career."

View story >


High-throughput sequencing outpaces flow cytometry for earliest detection of cancer relapse

Next-generation, high-speed DNA-decoding technology detects minimal residual disease in nearly double the number of leukemia patients than current gold standard method

May 21, 2012 | By Kristen Woodward

A study led by Fred Hutchinson Cancer Research Center Public Health Sciences Division computational biologist Dr. Harlan Robins has found that a next-generation, high-speed DNA-decoding technology called high-throughput sequencing can detect the earliest signs of potential relapse in nearly twice the number of leukemia patients as compared to flow cytometry, the current gold standard for detecting minimal residual disease.

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.